CA-ODASEVA
12.9.2019 14:02:14 CEST | Business Wire | Press release
Odaseva , the unified cloud data protection, compliance and operations platform for enterprises running Salesforce as a business-critical application, today announced that it has seen triple year over year growth, and after only seven years of operation, supports a staggering one trillion Salesforce records, with over 10 million enterprise-level internal Salesforce customers.
Odaseva’s explosive growth is in part due to the influx of new data privacy and governance laws such as GDPR or CCPA , demanding that businesses put in place specific regulations such as Data Subject Rights (which stipulates that consumers have the right to access their own private information) and leverage more robust data governance solutions to shield and manage private customer information. Odaseva, which began in 2012 with one client, Schneider Electric, has rapidly increased its enterprise customer base including Toyota France, Robert Half International and GE, offering organizations the ability to augment their existing cloud data protection solutions.
“Comprehensive compliance automation and data protection are essential for organizations coping with increasingly complex and costly privacy regulations as varied as HIPAA, GDPR, CCPA and PIPEDA,” says Sovan Bin, founder and CEO of Odaseva. “As confidential personal data is often distributed across multiple clouds, as well as on-premises data centers, our goal at Odaseva has been to introduce consistency in how audit information is gathered and presented as well as preserved, in order to provide a measure of relief for businesses striving to comply with multiple regulations.
“No other technology vendor today can offer such a unified cloud data governance suite for Salesforce as Odaseva,” Sovan Bin continued.
Recent Investments and Increased Headcount
In 2019, Odaseva raised $11.7m in Series A funding round, which brought the total funding for Odaseva to $14 million. The round was led by Partech with participation from new investor Salesforce Ventures and existing investor Serena. These new investments have allowed Odaseva to direct a portion of the new funding to build on existing sales and technology partnerships with Accenture, Capgemini, CGI, and Deloitte.
In addition, Odaseva has doubled their headcount in the past six months with new hires including a new chief legal officer and a vice president of customer and partner success.
Located in San Francisco and Paris, Odaseva continues to actively recruit in both locations and is looking to expand its operations globally.
Added New Products to Portfolio Line-up:
The hallmark of Odaseva’s solution lies in its compliance automation tools such as GDPR for Salesforce which allows the enterprise to automate a broad range of data procedures from backup to archival, audit, and more in order to comply with industry regulations.
However in 2019 alone, Odaseva announced several new tools to complete their portfolio that have included the following:
- Cockpit AI: With advanced machine learning capabilities, Cockpit AI offers the first predictive capacity management system to help enterprise Salesforce users maximize the value of the platform by automating the process of monitoring and forecasting the use of platform allocations – such as file storage, data storage and API calls on Salesforce
- Vault: Works with the Odaseva platform to help users automatically archive sensitive data that organizations are required to keep for long periods of time in regulated industries such as financial services, healthcare and insurance. Not only will the information be kept safe from any unauthorized users, but Odaseva ensures a data durability level of 99.999999999% over a given year.
- Full Sandbox Anonymization application (FSA) for Salesforce customers . The application works with the Odaseva platform to anonymize all personal information that an organization may put in a Salesforce Full Sandbox – which is an isolated copy of an organization’s Salesforce environment that can be used for training, development and testing.
About Odaseva
For enterprises that leverage Salesforce as a mission-critical application, Odaseva delivers enterprise-class data governance, providing data protection (backup and recovery, archiving, governor limits monitoring), data compliance for regulation requirements such as GDPR and data operations (Salesforce DX data extensions). Odaseva was engineered for Salesforce by Salesforce experts and is endorsed by Salesforce Ventures. Over 10+Million Salesforce Enterprise users from industry-leading companies such as Schneider Electric, Heineken and Robert Half trust Odaseva’s data governance platform.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190912005206/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ARIS Announced as Exclusive Process Intelligence Launch Partner for AWS European Sovereign Cloud8.6.2026 09:00:00 CEST | Press release
Partnership Will Enable Enterprises to Accelerate AI Adoption While Ensuring Digital Sovereignty ARIS, the process context foundation for enterprise AI deployment, today announced its collaboration with Amazon Web Services (AWS) to support organizations navigating increasingly complex digital sovereignty requirements while accelerating AI-driven transformation. Many European enterprises face growing pressure to ensure sensitive operational and business data remains under European governance and regulatory control. Through the AWS European Sovereign Cloud (ESC), they will be able to combine advanced cloud and AI capabilities with enhanced operational separation, EU-based governance, and strict data residency controls. ARIS will support customers looking to operationalize AI safely and at scale within these boundaries by providing the process intelligence, governance, and operational context required for trusted enterprise AI deployment. “AI is moving rapidly from experimentation to oper
Cosylab Launches PlanOne™ Treatment Planning System for Particle Therapy8.6.2026 08:00:00 CEST | Press release
Cosylab today announced the commercial launch of PlanOne™, a treatment planning system for particle therapy, bringing physics-accurate, radiobiologically informed planning and a unified clinical workflow into a single environment. PlanOne™ is FDA 510(k) cleared. "PlanOne™ began with listening. Over the years, our work on control systems in radiation oncology has put us in direct, ongoing contact with medical physicists and clinical teams at some of the leading facilities in the world," said Mark Pleško, CEO of Cosylab. "Our partners have been clear on what matters most for particle therapy: physics accuracy they can defend, clinical confidence at the point of plan approval, and a platform built to grow with AI and adaptive workflows. We designed PlanOne™ around those three priorities, and we'll keep developing it together with the clinical community that helped shape it." Physics-accurate, radiobiologically informed planning PlanOne™ is built on a GPU-accelerated Monte Carlo dose engin
BitGo MENA Launches Regulated Electronic Trading, Delivering Full Suite Trading Services to the Region8.6.2026 06:00:00 CEST | Press release
BitGo MENA FZE (“BitGo MENA”), a subsidiary of BitGo Holdings, Inc. (NYSE: BTGO) (“BitGo”), the digital asset infrastructure company, today announced the launch of electronic trading in the Middle East and North African (MENA). With this launch, clients can now access a comprehensive trading solution combining BitGo MENA’s established over-the-counter (OTC) trading offering with institutional-grade electronic execution, all operating under BitGo MENA’s Broker-Dealer license from Dubai’s Virtual Assets Regulatory Authority (VARA). The launch further expands BitGo MENA’s regulated product suite under VARA’s oversight, marking another step in the region’s continued buildout of institutional digital asset infrastructure amid growing demand for integrated execution and custody solutions. “The Middle East and North Africa has quickly become one of the most exciting regions in the world for digital assets, with regulators, institutions, and innovators moving with real purpose,” said Mike Bels
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press release
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - - Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
